Luminesce Alliance partner, the Sydney Children’s Hospitals Network has published an online paper on the use of Chimeric Antigen Receptor (CAR)-T cell therapy for patients with B cell malignancies, (such as oestosacroma and Ewing Sarcoma) in Cancer Gene Therapy.

Vector and CAR T-cell production are currently being developed at Westmead prior to early phase clinical trials.